11/10/2011

Mesoblast's mesenchymal precursor cells helped maintain lower fasting glucose levels in nonhuman primates with type 2 diabetes over eight weeks, the company announced. MPC-treated primates also had significant reductions in circulating C-reactive protein, a sign of cardiovascular disease risk, experts said.

Related Summaries